Vaccinex (NASDAQ:VCNX) Upgraded to Hold at Zacks Investment Research

Share on StockTwits

Zacks Investment Research upgraded shares of Vaccinex (NASDAQ:VCNX) from a sell rating to a hold rating in a report published on Friday, Zacks.com reports.

According to Zacks, “Vaccinex, Inc. is a clinical-stage immunotherapy company. It engages in the discovery and development of biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases and autoimmune disorders. The company’s product pipeline consists of VX15, VX5 and VX25 which are in clinical stage. Vaccinex, Inc. is based in Rochester, New York. “

VCNX stock opened at $4.09 on Friday. The firm’s 50-day moving average price is $5.33. Vaccinex has a 12-month low of $3.32 and a 12-month high of $12.00. The stock has a market capitalization of $46.98 million and a P/E ratio of -0.79.

Vaccinex (NASDAQ:VCNX) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.79) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.75) by ($0.04). The business had revenue of $0.09 million during the quarter. As a group, equities research analysts anticipate that Vaccinex will post -2.35 EPS for the current year.

Vaccinex Company Profile

Vaccinex, Inc, a clinical-stage biotechnology company, discovers and develops bio therapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders. Its lead product candidate is pepinemab that is in clinical development stage for the treatment of non-small cell lung cancer (NSCLC), osteosarcoma, melanoma, and Huntington's disease.

Read More: Dead Cat Bounce

Get a free copy of the Zacks research report on Vaccinex (VCNX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Vaccinex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vaccinex and related companies with MarketBeat.com's FREE daily email newsletter.